Gardos G, Cole J O
Am J Psychiatry. 1983 Feb;140(2):200-2. doi: 10.1176/ajp.140.2.200.
The evidence from the literature does not support the notion that psychotropic drugs with central anticholinergic properties (antiparkinsonian drugs, neuroleptics, antidepressants) constitute a risk factor in tardive dyskinesia. Antiparkinsonian drugs tend to produce reversible increases in the severity of dyskinetic movements and can be used as pharmacological probes in the assessment of neuroleptic-induced movement disorders.
具有中枢抗胆碱能特性的精神药物（抗帕金森病药物、抗精神病药物、抗抑郁药物）是迟发性运动障碍的一个风险因素。抗帕金森病药物往往会使运动障碍的严重程度出现可逆性增加，并且可作为评估抗精神病药物所致运动障碍的药理学探针。
